925 related articles for article (PubMed ID: 32640381)
41. Molecular pharmacology of ciclesonide against SARS-CoV-2.
Kimura H; Kurusu H; Sada M; Kurai D; Murakami K; Kamitani W; Tomita H; Katayama K; Ryo A
J Allergy Clin Immunol; 2020 Aug; 146(2):330-331. PubMed ID: 32593491
[No Abstract] [Full Text] [Related]
42. In silico identification of novel SARS-COV-2 2'-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches.
El Hassab MA; Ibrahim TM; Al-Rashood ST; Alharbi A; Eskandrani RO; Eldehna WM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):727-736. PubMed ID: 33685335
[TBL] [Abstract][Full Text] [Related]
43. SARS-CoV-2 envelope protein topology in eukaryotic membranes.
Duart G; García-Murria MJ; Grau B; Acosta-Cáceres JM; Martínez-Gil L; Mingarro I
Open Biol; 2020 Sep; 10(9):200209. PubMed ID: 32898469
[TBL] [Abstract][Full Text] [Related]
44. Alkamides and Piperamides as Potential Antivirals against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Gutierrez-Villagomez JM; Campos-García T; Molina-Torres J; López MG; Vázquez-Martínez J
J Phys Chem Lett; 2020 Oct; 11(19):8008-8016. PubMed ID: 32840378
[TBL] [Abstract][Full Text] [Related]
45. An insight into SARS-CoV-2 membrane protein interaction with spike, envelope, and nucleocapsid proteins.
Kumar P; Kumar A; Garg N; Giri R
J Biomol Struct Dyn; 2023 Feb; 41(3):1062-1071. PubMed ID: 34913847
[TBL] [Abstract][Full Text] [Related]
46. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
[TBL] [Abstract][Full Text] [Related]
47. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V
Elife; 2020 May; 9():. PubMed ID: 32452762
[TBL] [Abstract][Full Text] [Related]
48. A protein interaction map identifies existing drugs targeting SARS-CoV-2.
Cava C; Bertoli G; Castiglioni I
BMC Pharmacol Toxicol; 2020 Sep; 21(1):65. PubMed ID: 32883368
[TBL] [Abstract][Full Text] [Related]
49. Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2).
Sarkar B; Ullah MA; Johora FT; Taniya MA; Araf Y
Immunobiology; 2020 May; 225(3):151955. PubMed ID: 32517882
[TBL] [Abstract][Full Text] [Related]
50. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.
Pokhrel R; Chapagain P; Siltberg-Liberles J
J Med Microbiol; 2020 Jun; 69(6):864-873. PubMed ID: 32469301
[No Abstract] [Full Text] [Related]
51. A Comprehensive Mapping of the Druggable Cavities within the SARS-CoV-2 Therapeutically Relevant Proteins by Combining Pocket and Docking Searches as Implemented in Pockets 2.0.
Gervasoni S; Vistoli G; Talarico C; Manelfi C; Beccari AR; Studer G; Tauriello G; Waterhouse AM; Schwede T; Pedretti A
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708196
[TBL] [Abstract][Full Text] [Related]
52. Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein.
Yang C; Pan X; Xu X; Cheng C; Huang Y; Li L; Jiang S; Xu W; Xiao G; Liu S
Signal Transduct Target Ther; 2020 Oct; 5(1):220. PubMed ID: 33024075
[No Abstract] [Full Text] [Related]
53. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2.
Ling R; Dai Y; Huang B; Huang W; Yu J; Lu X; Jiang Y
Peptides; 2020 Aug; 130():170328. PubMed ID: 32380200
[TBL] [Abstract][Full Text] [Related]
54. Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase.
Abidi SH; Almansour NM; Amerzhanov D; Allemailem KS; Rafaqat W; Ibrahim MAA; la Fleur P; Lukac M; Ali S
Sci Rep; 2021 May; 11(1):10290. PubMed ID: 33986405
[TBL] [Abstract][Full Text] [Related]
55. Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products.
Khan A; Khan M; Saleem S; Babar Z; Ali A; Khan AA; Sardar Z; Hamayun F; Ali SS; Wei DQ
Interdiscip Sci; 2020 Sep; 12(3):335-348. PubMed ID: 32617855
[TBL] [Abstract][Full Text] [Related]
56. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov.
Zhang H; Saravanan KM; Yang Y; Hossain MT; Li J; Ren X; Pan Y; Wei Y
Interdiscip Sci; 2020 Sep; 12(3):368-376. PubMed ID: 32488835
[TBL] [Abstract][Full Text] [Related]
57. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
Parvez MSA; Karim MA; Hasan M; Jaman J; Karim Z; Tahsin T; Hasan MN; Hosen MJ
Int J Biol Macromol; 2020 Nov; 163():1787-1797. PubMed ID: 32950529
[TBL] [Abstract][Full Text] [Related]
58. In silico molecular docking: Evaluation of coumarin based derivatives against SARS-CoV-2.
Chidambaram SK; Ali D; Alarifi S; Radhakrishnan S; Akbar I
J Infect Public Health; 2020 Nov; 13(11):1671-1677. PubMed ID: 33008777
[TBL] [Abstract][Full Text] [Related]
59. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.
Hage-Melim LIDS; Federico LB; de Oliveira NKS; Francisco VCC; Correia LC; de Lima HB; Gomes SQ; Barcelos MP; Francischini IAG; da Silva CHTP
Life Sci; 2020 Sep; 256():117963. PubMed ID: 32535080
[TBL] [Abstract][Full Text] [Related]
60. Structural analysis of experimental drugs binding to the SARS-CoV-2 target TMPRSS2.
Huggins DJ
J Mol Graph Model; 2020 Nov; 100():107710. PubMed ID: 32829149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
